Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis (RMS)

Drug Category : Array
Conference Category : Array
Lead Author : Fox E, et al.
Published Date : 28/02/2019
Download Link : https://www.tgtherapeutics.com/Final%20ACTRIMS%202019%20Poster.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top